Mortality from any cause (tibolone 2.5 mg/d) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes mortality from any cause (tibolone 2.5 mg/d) compared with combined HT (very low certainty).
1 finding from 1 review
Vasomotor symptoms (tibolone 2.5 mg/d) · postmenopausal women with vasomotor symptoms
Tibolone probably leads to higher vasomotor symptoms (tibolone 2.5 mg/d) compared with combined HT (moderate certainty).
1 finding from 1 review
Vasomotor symptoms (all doses) · postmenopausal women with vasomotor symptoms
Tibolone probably leads to lower vasomotor symptoms (all doses) compared with placebo (moderate certainty).
1 finding from 1 review
Unscheduled bleeding (all doses) · postmenopausal women with or without vasomotor symptoms
Tibolone probably leads to lower unscheduled bleeding (all doses) compared with combined HT (moderate certainty).
1 finding from 1 review
Endometrial cancer · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes endometrial cancer (all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Breast cancer; women without previous breast cancer (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes breast cancer; women without previous breast cancer (all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Venous thromboembolic events · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes venous thromboembolic events (clinical evaluation; all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Cardiovascular events · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes cardiovascular events (all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Cerebrovascular event (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes cerebrovascular event (all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Endometrial cancer · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes endometrial cancer (all doses) compared with placebo (very low certainty).
1 finding from 1 review
Breast cancer; women without previous breast cancer (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes breast cancer; women without previous breast cancer (all doses) compared with placebo (very low certainty).
1 finding from 1 review
Unscheduled bleeding (all doses) · postmenopausal women with or without vasomotor symptoms
Tibolone probably leads to higher unscheduled bleeding (all doses) compared with placebo (moderate certainty).
1 finding from 1 review
Venous thromboembolic events · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes venous thromboembolic events (clinical evaluation) all doses compared with placebo (very low certainty).
1 finding from 1 review
Cardiovascular events · postmenopausal women with or without vasomotor symptoms
1 finding from 1 review
Cerebrovascular event (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes cerebrovascular events (all doses) compared with placebo (very low certainty).
1 finding from 1 review
Mortality from any cause (all doses) · postmenopausal women with or without vasomotor symptoms
Tibolone showed no clear difference in mortality from any cause (all doses) compared with placebo (low certainty).
1 finding from 1 review
Uterine bleeding · patients with uterine fibroids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of vasomotor symptoms · patients with uterine fibroids
1 finding from 1 review
Rate of vasomotor symptoms ‐ · patients with uterine fibroids
GnRH‐a + tibolone showed no clear difference in rate of vasomotor symptoms ‐ compared with gnRH‐a ± placebo (low certainty).
1 finding from 1 review
QoL · patients with uterine fibroids
1 finding from 1 review